Premium
Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8 + PD ‐1 − tumor‐infiltrating T cells in PD‐L1 ‐enriched tumor microenvironment
Author(s) -
Eissa Ibrahim Ragab,
Mukoyama Nobuaki,
Abdelmoneim Mohamed,
Naoe Yoshinori,
Matsumura Shigeru,
BustosVillalobos Itzel,
Ichinose Toru,
Miyajima Noriyuki,
Morimoto Daishi,
Tanaka Maki,
Fujimoto Yasushi,
Sone Michihiko,
Kodera Yasuhiro,
Kasuya Hideki
Publication year - 2021
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.33550
Subject(s) - cd8 , immune system , tumor microenvironment , oncolytic virus , cytotoxic t cell , t cell , cancer research , chemistry , tumor infiltrating lymphocytes , antigen , biology , immunology , in vitro , biochemistry
Oncolytic viruses (OVs) remodel the tumor microenvironment by switching a “cold” tumor into a “hot” tumor with high CD8 + T‐cell infiltration. CD8 + T‐cell activity plays an essential role in the antitumor efficacy of OVs. However, the activity of T cells is impaired by the programmed cell death protein‐1/programmed cell death‐ligand 1 (PD‐1/PD‐L1) interaction. To date, it remains unclear why OVs alone have a significant antitumor activity even when PD‐L1 expression persists on tumor or immune cells. In this study, we found that canerpaturev (C‐REV) treatment significantly suppressed tumor growth, even though it induced a significant increase in PD‐L1 expression in tumors in vivo as well as persistence of high PD‐L1 expression on antigen‐presenting cells (macrophage and dendritic cells [DCs]). Surprisingly, we observed that C‐REV treatment increased the abundance of activated CD8 + PD‐1 − tumor‐infiltrating lymphocytes (TILs) in the tumor on both the injected and contralateral sides, although infiltration of CD8 + PD‐1 high TILs into the tumor was observed in the control group. Moreover, the difference in PD‐1 expression was observed only in tumors after treatment with C‐REV, whereas most CD8 + T cells in the spleen, tumor‐draining lymph nodes and blood were PD‐1‐negative, and this did not change after C‐REV treatment. In addition, changes in expression of T‐cell immunoglobulin and mucin‐domain containing‐3 and T‐cell immune‐receptor with Ig and ITIM domains were not observed on CD8 + TILs after C‐REV treatment. Taken together, our findings may reveal mechanisms that allow OVs to trigger an antitumor immune response, irrespective of a PD‐L1‐enriched tumor microenvironment, by recruitment of CD8 + PD‐1 − TILs.